Home » Newsletters » BioWorld Science

BioWorld Science

March 8, 2001

View Archived Issues

Xenova makes substantial progress during 2000; announces proposed merger with Cantab

Neose Technologies and Novazyme restructure enzyme replacement therapy agreement

First patient inoculated in phase I trial of first AIDS vaccine specifically designed for Africa

Pharmagenesis secures new funding to support development of two drug candidates

Cellegy seeks marketing approval for Rectogesic in South Korea

Celltech and Pharmacia to codevelop and copromote CDP-870

Roche MMPI examined for population pharmacokinetics in osteoarthritis patients

ASCPT news: topical lidocaine proves effective and safe in the treatment of migraine

Ligocyte technology shows promise for antiinfective drug discovery

Patient recruitment begins in phase II trial of E21R for the treatment of CMML

Novel therapeutic approach to rheumatoid arthritis: PPARgamma ligands

Lilly's Zovant appears to be a major advance in the treatment of sepsis

Phase Ib trial of RK-0202 for oral mucositis to commence shortly

Mayo Clinic presents data on new aldehyde dehydrogenase inhibitor at ASCPT meeting

Antiinfective DB-289 successfully completes single-dose phase I trial

Cell Genesys initiates phase I/II trial of GVAX cancer vaccine for multiple myeloma

Pharmacokinetics and tolerability of Ro-09-4889 explored in humans

Pharmacia acquires Sensus; Somavert under review at the FDA

Phase I/II pharmacokinetic and safety data reported at AAD for Atrisone

FDA accepts IntraDose NDA filing

Immunogenic peptides claimed for the treatment of HPV infection

Gene associated with renal disease discovered by Gene Logic

Nucleic acid delivery compounds and compositions for therapeutic use

New Schering compounds useful in diagnosis and therapy of prostate disorders

Indoles and indazoles from NPS Allelix particularly useful for migraine therapy

Novel, orally active androgens designed and tested at Akzo Nobel

EMD-273040: a new cyclic peptide integrin receptor antagonist

Sanofi-Synthelabo presents new CRF antagonists and potential therapeutic uses

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 10, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...